image description

Tag: lupus therapeutics

Dr. Daniel Wallace Appointed to Lupus Therapeutics Board

New York, NY, July 18, 2019 — The Lupus Research Alliance (LRA) affiliate Lupus Therapeutics is pleased to announce that Daniel Wallace, MD joins as a new member of its Board of Directors.  Including lupus patients, family members and scientists, this governing body provides strategic insight and financial oversight to help the organization achieve its mission – […] Read More

A Promising New Therapy

April, 2019 As our name implies, the Lupus Research Alliance aims to forge partnerships and bring other players  to the table to better understand and treat lupus — and our latest venture holds the promise of a new therapy. We — and our affiliate, Lupus Therapeutics — are about to collaborate with Takeda Pharmaceutical Company […] Read More

LRA Addressing Health Disparities Among Vulnerable Groups

February 20, 2020 The Lupus Research Alliance (LRA) works hard, often in concert with organizations like the National Minority Quality Forum to alleviate disparities in healthcare among groups at particular risk for lupus, including African-Americans as the group hardest hit by the disease.  Several programs educate healthcare providers, patients and the public to better recognize […] Read More

Lupus Therapeutics Announces Collaboration to Support the Evaluation of Non-Genetically Modified Cell-Based Therapy for Lupus Nephritis with Artiva Biotherapeutics

NEW YORK, N.Y. — [March 14, 2024]: Lupus Therapeutics, the clinical research affiliate of the Lupus Research Alliance, announced a collaboration with Artiva Biotherapeutics, Inc. on a Phase 1 trial of the company novel NK cell-based therapy AlloNK® (also known as AB-101), in combination with anti-CD20 antibodies, for patients with active lupus nephritis – inflammation […] Read More

Lupus Peer-to-Peer Early Education Program Expands

March 28, 2024 Lupus Therapeutics, the clinical research affiliate of the Lupus Research Alliance, has announced an innovative expansion of the highly successful Patient Advocates for Lupus Studies (PALS) program with the introduction of a first-in-lupus “Trial Buddy” component made possible by a partnership with Bristol Myers Squibb. The Trial Buddy addition provides extra support […] Read More

Meet Unstoppable Advocate for Minority Health Christopher Reed

April 2, 2024 Determined to alleviate healthcare disparities for minorities, J. Christopher Reed, JD, urges our lupus community to use the power of National Minority Health Month to spotlight the issue this April. First diagnosed at 16, Christopher fought debilitating lupus symptoms to graduate college in eight years and then Tulane University Law School in […] Read More

Lupus Therapeutics Announces Partnership to Support the Evaluation of Natural Killer (NK) Cell Therapy in Lupus Nephritis

NEW YORK, N.Y. — October 17, 2023: Lupus Therapeutics, the clinical research affiliate of the Lupus Research Alliance, today announced a partnership with Nkarta, Inc. (Nasdaq: NKTX), a biopharmaceutical company developing the engineered natural killer (NK) cell therapy NKX019 for refractory lupus nephritis that has not responded to standard treatment. Lupus Therapeutics has provided advisory […] Read More

Championing Patient Power in Lupus

January 24, 2024 Dr. Stacie Bell came to LRA’s clinical research affiliate Lupus Therapeutics (LT) one year ago to help fulfill the vision of an entire community united to triumph over a complex and confounding disease.  She joined determined to work with the researchers, clinicians, biopharmaceutical companies, and most importantly the people with lupus and […] Read More

LRA Highlights Groundbreaking Lupus Research at ACR Convergence 2023

This information is brought to you by the Lupus Research Alliance and Lupus Therapeutics and is not sponsored by, nor a part of, the American College of Rheumatology.  30+ presentations of studies funded by the LRA spanning a broad spectrum of research areas Positive results from Phase 2/3 clinical studies supported by LRA affiliate Lupus Therapeutics point to […] Read More

Investigational CAR T Cell Gets Fast Tracked by U.S. FDA

May 1, 2023 The LRA and our clinical arm Lupus Therapeutics are pleased to share good news from Cabaletta Bio, Inc. that the U.S. Food and Drug Administration (FDA) has granted Fast Track Designation for CABA-201, a CAR T cell investigational therapy in development to treat systemic lupus erythematosus and lupus nephritis – a common […] Read More
Stay informed about events, research developments, and ways you can help. Sign up for updates